Soligenix Inc (SNGX): Recombinant protein subunit SARS-CoV-2 v...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	3
Posts	253
Boards Moderated	0
Alias Born	08/23/2007

Maps0117

Re: None

Tuesday, 05/04/2021 6:06:02 PM

Tuesday, May 04, 2021 6:06:02 PM

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.

Competing Interest Statement
Axel T. Lehrer and Oreola Donini are named inventors on a patent application covering a recombinant subunit vaccine for SARS-CoV-2. David E. Clements and James T. Senda, are current employees of Hawaii Biotech Inc. Laurent Pessaint and Hanne Andersen are current employees of BIOQUAL, Inc. Oreola Donini is a current employee of Soligenix Inc. We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

https://www.bioqual.com/https://

finance.yahoo.com/quote/BIOQ?p=BIOQ&guccounter

News coming soon SNGX buys BIOQ

https://www.biorxiv.org/content/10.1101/2021.03.02.433614v1

Go SNGX